EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study

Gimena Hernández, Olatz Garín, Alexandra L. Dima, Àngels Pont, Marc Martí, Jordi Alonso, Éric Van Ganse, Laurent Laforest, Marijn de Bruin, Karina Mayoral, Vicky Serra‐Sutton, Montse Ferrer, Astro-lab GroupJournal of Medical Internet Research 2018 · DOI

TL;DR

This study validates the new 5-level EuroQol (EQ-5D-5L) questionnaire for assessing the quality of life in adults with asthma. The EQ-5D-5L demonstrated good reliability and construct validity, showing it can effectively differentiate between groups with varying asthma control and chronic conditions, making it a promising tool for eHealth programs monitoring asthma patients.

What Problem Does This Paper Address?

The EuroQol Group's original EQ-5D questionnaire, a widely used tool for measuring health-related quality of life (HRQoL), has a known limitation: a "ceiling effect." This means that a significant portion of patients, especially those with milder conditions, report the best possible health state, making it difficult to detect subtle improvements or differences in HRQoL. To address this, the EQ-5D-5L was developed with more response options (5 levels instead of 3) to increase its sensitivity. While the EQ-5D-5L has been tested in other patient groups, its metric properties, specifically its validity and reliability in assessing HRQoL in adults with asthma, had not yet been evaluated. This study aims to fill that gap.

Methods

The researchers conducted a cross-sectional study involving adults aged 18-40 with persistent asthma, recruited from primary care settings in France and England. Participants self-completed the EQ-5D-5L questionnaire online. To calculate the EQ-5D index, they used two different preference value sets: the English preference value set for the EQ-5D-5L and a French 3L-5L crosswalk value set.

The study evaluated several aspects of the EQ-5D-5L:

  • Distribution: They examined response patterns across the EQ-5D-5L dimensions and calculated the EQ-5D index distribution, including ceiling and floor effects.
  • Construct Validity: This was assessed by comparing EQ-5D-5L scores between groups of patients hypothesized to differ in their HRQoL. These "known groups" were defined by factors like the number of chronic conditions, the number of short-acting beta-agonist (SABA) canisters prescribed in the past year, SABA use in the last 4 weeks, and asthma control levels (measured by the Asthma Control Questionnaire - ACQ).
  • Reliability: Internal consistency was measured using Cronbach's alpha.

Datasets

The study utilized data from the ASTRO-LAB cohort, a prospective longitudinal study of asthmatic patients. The primary dataset for this analysis consisted of baseline data from 312 patients who completed the Web-based survey, with 279 ultimately included in the final analysis after exclusions. No new benchmarks were introduced; the study focused on evaluating an existing instrument.

Key Insights and Ideas

  • Improved Sensitivity: The EQ-5D-5L appears to be more sensitive than its predecessor (EQ-5D-3L) in the asthma population, as evidenced by a lower ceiling effect compared to previous studies. This suggests it can better capture the nuances of HRQoL in this group.
  • Web-Based Feasibility: The high completion rate of the EQ-5D-5L via a Web-based survey (93%) indicates that this administration method is feasible and well-accepted by asthma patients, supporting its use in eHealth programs.
  • Value Set Comparison: The study found that using either the English EQ-5D-5L value set or the French 3L-5L crosswalk value set yielded similar results for the EQ-5D-5L index, suggesting the crosswalk is a reasonable interim solution until a definitive French EQ-5D-5L value set is available.
  • Discriminatory Power: The EQ-5D-5L effectively distinguished between groups with different levels of asthma control and varying numbers of chronic conditions, a key indicator of its construct validity.

Key Results

  • Ceiling Effect: The ceiling effect for the EQ-5D-5L was 26.5% (74/279), which is lower than ceiling effects reported for the EQ-5D-3L in previous asthma studies (e.g., 59% and 50%). The floor effect was null.
  • EQ-5D-5L Index: The mean EQ-5D-5L index was 0.88 (SD 0.14) using the English value set and 0.83 (SD 0.19) using the French 3L-5L crosswalk value set.
  • Construct Validity: Large effect sizes were observed for groups defined by asthma control (ACQ scores), with effect sizes of 1.06 and 1.04 between well-controlled and not well-controlled asthma groups. Moderate effect sizes (around 0.5) were found for groups defined by chronic conditions and SABA use.
  • Reliability: Cronbach's alpha was 0.69, which is considered acceptable for internal consistency.
  • Web-Based Participation: 53.7% of the initial cohort completed the Web-based survey, and 92.9% of those who started the survey completed the EQ-5D-5L.

Limitations and Future Work

The authors acknowledge several limitations:

  • Direct Comparison: A direct comparison with the EQ-5D-3L was not possible due to differences in study populations and designs. While the EQ-5D-5L showed better properties, these differences might not be solely attributable to the instrument itself.
  • No Asthma-Specific Measure: The study did not include an asthma-specific HRQoL measure, preventing a direct comparison of the EQ-5D-5L's performance against such instruments.
  • Web-Based Only: All patients completed the EQ-5D-5L online, so the usability of this mode compared to others (e.g., telephone) could not be assessed.
  • Generalizability: The study focused on mild-to-moderate persistent asthma patients aged 18-40. Results may not generalize to patients with intermittent or severe persistent asthma, or those older than 40.
  • Non-response Bias: While demographic and clinical characteristics were similar between respondents and non-respondents, potential differences in unmeasured psychological traits could exist.

Future work should focus on evaluating the responsiveness of the EQ-5D-5L over time in asthma patients and conducting head-to-head comparisons with disease-specific instruments to assess sensitivity to change.

Summary updated

Abstract

BACKGROUND: The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. OBJECTIVE: This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. METHODS: We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as >6 months of prescribed inhaled corticosteroids and long-acting beta-agonists or inhaled corticosteroids alone during the 12 months prior to inclusion. The EQ-5D index was obtained by applying the English preference value set for the new EQ-5D-5L and the French 3L-5L crosswalk value set. Both value sets produced single preference-based indices ranging from 1 (best health state) to negative values (health states valued as worse than death), where 0=death, allowing the calculation of quality-adjusted life years. Responses to dimensions and index distribution, including ceiling and floor effects, were examined. The construct validity was assessed by comparing the means of known groups by analyses of variance and calculation of effect sizes. RESULTS: Of 312 patients answering the baseline Web-based survey, 290 completed the EQ-5D-5L (93%). The floor effect was null, and the ceiling effect was 26.5% (74/279). The mean EQ-5D-5L index was 0.88 (SD 0.14) with the English value set and 0.83 (SD 0.19) with the French 3L-5L crosswalk value set. In both indices, large effect sizes were observed for known groups defined by the Asthma Control Questionnaire (1.06 and 1.04, P<.001). Differences between extreme groups defined by chronic conditions (P=.002 and P=.003 for the English value set and French 3L-5L crosswalk value set, respectively), short-acting beta-agonists (SABAs) canisters in the last 12 months (P=.02 and P=.03), or SABA use during the previous 4 weeks (P=.03 and P=.01) were of moderate magnitude with effect sizes around 0.5. CONCLUSIONS: The new EQ-5D-5L questionnaire has an acceptable ceiling effect, a good construct validity based on the discriminant ability for distinguishing among health-related known groups, and high reliability, supporting its adequacy for assessing the HRQoL in patients with asthma. EQ-5D-5L completion by most Web-based respondents supports the feasibility of this administration form.
BibTeX
@article{hernandez2018euroqol,
  author = {Gimena Hernández and Olatz Garín and Alexandra L. Dima and Àngels Pont and Marc Martí and Jordi Alonso and Éric Van Ganse and Laurent Laforest and Marijn de Bruin and Karina Mayoral and Vicky Serra‐Sutton and Montse Ferrer and ASTRO-LAB Group},
  title = {{EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study}},
  journal = {Journal of Medical Internet Research},
  year = {2018},
  doi = {10.2196/10178},
}
Figure